Monolaurin, a fat-derived compound made from the main fatty acid in coconut oil and sold as a supplement for immune and gut support, is a plausible but largely unproven tool. Gels applied in the nose or vagina reduced certain microbes, but no study has tested oral monolaurin for preventing infections, slowing aging or extending life. Risks appear low at food-like amounts; gram-level daily use has never been systematically studied. (Full Review)

Protocol

Manufacturer protocol (Lauricidin)

One blue scoop per meal (about 3 g)

A few pellets in week one, building up; split into 2–3 doses daily, taken with meals

Functional-medicine protocol

3 g three times daily (9 g/day)

Used in small intestinal bacterial overgrowth protocols; 300 or 600 mg capsules need 15–30 daily to match

Topical research regimens

5% monolaurin gel for 3 days

Swabbed into the nostrils, or vaginal gel twice daily

Time to effect

Nasal S. aureus reduction

Within 3 days

Topical 5% monolaurin gel

Oral use: viral load (HIV pilot)

6 months

Small falls at 6 months but not at 3; uncontrolled

Benefits

Low: Topical suppression of Staphylococcus aureus colonization and toxins; vaginal yeast and bacterial vaginosis; lower risk of COVID-19 infection; clearance of oral Helicobacter pylori; persistent Lyme disease symptoms; antiviral activity against enveloped viruses

Speculative: Protection against drug-resistant and invasive Staphylococcus aureus infection; gut microbiota and metabolic health; protection against intestinal inflammation

Contraindications

Pregnant or breastfeeding women at supplemental doses

People with known allergy to coconut or palm kernel products (theoretical)

Organ-transplant recipients and others on immunosuppressive therapy (theoretical)

People with recurrent genital herpes, for vaginal monolaurin products (theoretical; mouse data)

Key Interactions

Oral antibiotics (amoxicillin, cefalexin; fluoroquinolones such as ciprofloxacin): Monitor (theoretical)

Lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe): Monitor (theoretical)

Narrow-margin oral drugs (levothyroxine, warfarin, digoxin): Monitor (theoretical)

Orlistat (over-the-counter Alli): Caution (theoretical)

Over-the-counter vaginal antifungals and glycol-based lubricants (miconazole, clotrimazole, warming gels): Caution (theoretical)

Antimicrobial supplements (oregano oil, caprylic acid, berberine): Monitor (theoretical)

Coconut oil and medium-chain triglyceride (MCT) oil: Monitor (theoretical)

Vaccination: Monitor (theoretical)

Risk & Side Effects

Low: Local genital irritation; higher low-density lipoprotein cholesterol and triglycerides; digestive upset and "die-off" reactions

Speculative: Suppression of immune cell activation; increased genital herpes susceptibility with vaginal use; weight gain and gut imbalance at low doses; allergic reactions in coconut- or palm-sensitive people

Monitoring

Marker	Target	Why
LDL cholesterol	<100 mg/dL	Safety check: lauric acid may raise it
Absolute lymphocyte count	1.0–4.8 × 10⁹/L	Safety check: theoretical immune-cell suppression
Nasal or vaginal culture for the target microbe	No established target; change from the individual's own baseline	Colonization is expected to fall

Cadence: Baseline lipid panel (plus complete blood count and target culture where relevant); lipid panel at 8–12 weeks, then every 6–12 months during continued use; repeat cultures 1–4 weeks after a course; complete blood count at 3 months, then yearly for people with immune conditions

Qualitative Assessment

Frequency and duration of colds, cold sores or other recurrent infections compared with the prior year
Digestive tolerance (bloating, loose stools, reflux) during titration
Vaginal or nasal symptoms when topical or targeted use is the goal
Energy and general well-being during and after a course

Monolaurin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment